Flamma expands into the US

Flamma, an Italian pharmaceutical contract development and manufacturing organization (CDMO), has acquired Teva Pharmaceutical Industries’ chemical synthesis center in Malvern, Pennsylvania. Financial details were not disclosed. The 3,700 m2 facility near Philadelphia will net Flamma its first research and manufacturing asset for active pharmaceutical ingredients (APIs) in North America. The company has two such sites in Italy and one in China. The purchase brings Flamma about 1,800 m2 of laboratory space. In addition, the site features a pilot plant with hydrogenation capabilities comprised of four reactors ranging from 200 to 400 L, six standard kilo-lab suites, and one kilo-lab suite for highly-potent API production. The plant will be dedicated to developing APIs from the preclinical stage to small-volume commercial production. The former Teva facility, which closed last year, also has room for expansion. Flamma expects to employ 60 people there by 2023, according to Kenneth Drew, senior director of North